Andrade Rafael S, Kesler Kenneth A, Wilson Jamison L, Brooks Jo Ann, Reichwage Brett D, Rieger Karen M, Einhorn Lawrence H, Brown John W
Department of Surgery, Thoracic Division, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
Ann Thorac Surg. 2004 Oct;78(4):1224-8; discussion 1228-9. doi: 10.1016/j.athoracsur.2004.03.081.
Treatment of nonseminomatous germ cell tumors frequently requires bleomycin-combination chemotherapy followed by resection of residual disease. Bleomycin administration however raises concerns with respect to postoperative respiratory complications, particularly for patients undergoing large pulmonary resections. We undertook an institutional review to determine the outcome of large pulmonary resections after bleomycin-combination chemotherapy.
Between 1981 and 2001, 530 patients presented to our institution for resection of residual intrathoracic disease for either metastatic testicular or primary mediastinal nonseminomatous germ cell tumors. We subsequently reviewed 32 of these patients who required pneumonectomy (n = 19; RIGHT = 9, LEFT = 10) or bilobectomy (n = 13) after bleomycin-combination chemotherapy.
There were four operative deaths (13%). All postoperative deaths occurred in patients undergoing right-sided resections (pneumonectomy, n = 2; bilobectomy, n = 2) as a consequence of pulmonary complications. Operative survivors had a pulmonary morbidity of 18%. Fourteen of 20 long-term survivors were found to have a satisfactory performance status at follow-up.
Otherwise young and healthy male nonseminomatous germ cell tumors patients requiring large pulmonary resections after bleomycin-combination chemotherapy appear to be at higher than anticipated risk for pulmonary-related morbidity and mortality. However long-term survivors report an acceptable functional status.
非精原细胞瘤性生殖细胞肿瘤的治疗通常需要博来霉素联合化疗,随后切除残留病灶。然而,博来霉素的使用引发了对术后呼吸并发症的担忧,尤其是对于接受大型肺切除术的患者。我们进行了一项机构审查,以确定博来霉素联合化疗后大型肺切除术的结果。
1981年至2001年间,530例患者因转移性睾丸或原发性纵隔非精原细胞瘤性生殖细胞肿瘤的残留胸内病灶切除而就诊于我们机构。随后,我们回顾了其中32例在博来霉素联合化疗后需要进行肺叶切除术(n = 19;右侧 = 9,左侧 = 10)或双叶切除术(n = 13)的患者。
有4例手术死亡(13%)。所有术后死亡均发生在接受右侧切除术的患者中(肺叶切除术,n = 2;双叶切除术,n = 2),原因是肺部并发症。手术幸存者的肺部发病率为18%。20例长期幸存者中有14例在随访中表现出令人满意的功能状态。
否则,在博来霉素联合化疗后需要进行大型肺切除术的年轻健康男性非精原细胞瘤性生殖细胞肿瘤患者似乎面临高于预期的肺部相关发病率和死亡率风险。然而,长期幸存者报告功能状态可接受。